

Final Agenda
37th meeting of the Committee for Risk Assessment

23 May – 3 June 2016

ECHA Conference Centre (Annankatu 18, Helsinki)

**23 May starts at 14.00
27 May breaks at 13.00
30 May resumes at 14.00
3 June ends at 13.00**

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

**RAC/A/37/2016
For adoption**

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Report from other ECHA bodies and activities

- a) Report on RAC 36 action points, written procedures and update on other ECHA bodies

RAC/37/2016/01

**RAC/37/2016/02
Room document**

For information

- b) RAC workplan for all processes

For information

Item 5 – Requests under Article 77 (3)(c)

No requests.

Item 6 – Requests under Article 95 (3)

- a) 1-methyl-2-pyrrolidone (NMP)

RAC/37/2016/03

Restricted document

For discussion and agreement

- b) OEL-DNEL methodology request

For information

Item 7 – Harmonised classification and labelling (CLH)**7.1 CLH dossiers****A. Hazard classes for agreement without plenary debate (fast-track)**

- a) Phosmet (ISO)
acute toxicity (all routes), germ cell mutagenicity, carcinogenicity, reproductive toxicity (developmental effects)
- b) Pinoxaden (ISO)
physical hazards, acute toxicity (all routes), serious eye damage / eye irritation, aspiration hazard, environmental hazards
- c) Quizalofop-p-tefuryl
physical hazards, acute toxicity (all routes), skin corrosion/irritation, serious eye damage / eye irritation, respiratory sensitisation, germ cell mutagenicity, environmental hazards
- d) S-methoprene
physical hazards, acute toxicity (all routes of exposure), skin corrosion / irritation, serious eye damage / eye irritation, respiratory / skin sensitisation, STOT RE, germ cell mutagenicity, aspiration hazard, environmental hazards
- e) Isoproturon (ISO)
environmental hazards

B. Hazard classes for agreement with plenary debate

- f) Acetaldehyde, ethanal
- g) Epsilon-metofluthrin
- h) Phosmet (ISO)
- i) Pinoxaden (ISO)
- j) Quizalofop-P-tefuryl
- k) S-methoprene
- l) Sodium hypochloride, solution ... % Cl active
- m) 4-tert-butylphenol
- n) Isoproturon (ISO)
- o) Isobutyl methacrylate

For discussion and adoption

7.2 Appointment of RAC (co-)rapporteurs for CLH dossiers

RAC/37/2016/04

Restricted room document

For agreement

Item 8 – Restrictions

8.1 General restriction issues

- a) Capacity building - Carcinogenicity dose-response relationship setting for cobalt salts

RAC/37/2016/05

For discussion/agreement

- b) Update on Forum restriction projects

For information

8.2 Restriction Annex XV dossiers

- a) Conformity check
 - 1) TDFAs – outcome of the conformity check and presentation of the key issues
 - 2) Diisobutyl phthalate (DIBP), Dibutyl phthalate (DBP), Benzyl butyl phthalate (BBP), Bis(2-ethylhexyl) phthalate (DEHP) – outcome of the conformity check and presentation of the key issues

For agreement

8.3 Appointment of (co-)rapporteurs for restriction dossiers

For information

Item 9 – Authorisation

9.1 General authorisation issues

- a) Capacity building
 - 1. DNEL setting for the reprotoxic properties of 1-bromopropane
 - 2. DNEL setting for the reprotoxic properties of diisopentylphthalate (DIPP)
 - 3. Carcinogenicity dose-response relationship setting for aluminium and zirconium refractory ceramic fibres (Al- and Zr RCFs)

RAC/37/2016/06

RAC/37/2016/07

RAC/37/2016/08

For discussion and/or agreement

- b) Applications for authorisation received in the May submission window

For information

- c) Forum project on enforcement of authorisations

For information

- d) Report on the AfA Task Force Activities

For information

9.2 Authorisation applications

- a) Outcome of the conformity check and presentation of the key issues

1. Chromium trioxide_SNECMA
2. Chromium trioxide_MTU
3. Chromium trioxide_ABLOY
4. Chromium trioxide_HOOGOVENS Court Roll Surface Technologies
5. Chromium trioxide_TOPOCROM GmbH
6. Chromium trioxide_FN HERSTAL S.A.
7. Chromium trioxide_GERARDHI KUNSTOFFTECHNIK GmbH
8. Chromium trioxide; Potassium dichromate; Sodium dichromate_SOURIAU SAS
9. Chromium trioxide_HAPPOC
10. Ammonium dichromate_VECO BV
11. Potassium dichromate_GENTROCHEMA BV
12. Sodium dichromate_GENTROCHEMA BV
13. Sodium dichromate_TOTAL RAFFINERIE MITTELDEUTSCHLAND GmbH
14. Sodium dichromate_JACOBS DOUWEE EGBERTS DE GmbH
15. EDC_BASF SE
16. EDC_ELI LILLY S.A.
17. EDC_DOW ITALIA S.R.L.
18. EDC_LANXESS Deutschland GmbH
19. EDC_H&R OLWERKE SCHINDLER GmbH
20. EDC_GRUPPA LOTOS S.A.
21. EDC_GE HEALTHCARE Bio-Sciences
22. Diglyme_ROCHE DIAGNOSTIC GmbH
23. Diglyme_LIFE TECHNOLOGIES A.S.
24. Diglyme_BRACCO IMAGING S.P.A.
25. Diglyme_MAFLON S.P.A.
26. Diglyme_ACTON TECHNOLOGIES Limited
27. Diglyme_ISOCHEM
28. Technical MDA_POLYNT COMPOSITES France
29. EDC_EURENCO

For discussion and agreement

- b) Agreement on Draft Opinions

1. Chromium trioxide 1 (5 uses) (CT_Lanxess)
2. Sodium dichromate-Akzo Nobel (2 uses) (SD_Akzo)
3. Sodium dichromate-Solvay (1 use) (SD_Solvay)
4. Sodium dichromate-Arkema (1 use) (SD_Arkema)
5. Sodium dichromate-Ercros (1 use) (SD_Ercros)
6. Sodium dichromate-Electroquimica (1 use) (SD_ELECTRQUIMICA)

7. Sodium dichromate-Kemira (1 use) (SD_Kemira)
8. Sodium dichromate-Caffaro Brescia (1 use) (SD_Caffaro)
9. Chromium trioxide-Federal-Mogul Friedberg (1 use) (CT_Friedberg)
10. Chromium trioxide-Federal-Mogul Valvetrain (1 use) (CT_Valvetrain)
11. Chromium trioxide-Federal-Mogul Burscheid (1 use) (CT_Burscheid)
12. Chromic acid-Bosch (1 use) (CA_Bosch)
13. Chromium trioxide-Circuit Foil Luxembourg (1 use) (CT_Circuit)
14. Arsenic acid-Circuit Foil Luxembourg (1 use) (AsA_Circuit)
15. Chromium trioxide and dichromium tris(chromate)-Nexter Mechanics (4 uses) (CT_DtC_Nexter)
16. Chromium trioxide-Praxair (2 uses) (CT_Praxair)
17. Potassium dichromate-Sofradir (2 uses) (PD_Sofradir)
18. Sodium dichromate-Lanxess (1 use) (SD_Lanxess)
19. Ammonium dichromate-Micrometal (1 use) (AD_Micrometal)
20. Chromium trioxide-Cromomed (1 use) (CT_Cromomed)
21. Chromium trioxide-Rimex Metals (1 use) (CT_Rimex)
22. EDC-BASF (EDC_BASF)
23. Diglyme-Novartis (Diglyme_Novartis)

For discussion and agreement

c) Orientation discussion

1. Sodium dichromate-Brenntag (3 uses) (SD_Brenntag)
2. Potassium dichromate-Brenntag (2 uses) (PD_Brenntag)
3. Dichromium tris(chromate)-Henkel (2 uses) (DtC_Henkel)
4. Strontium chromate-Akzo Nobel (2 uses) (SC_Akzo)
5. Potassium hydroxyoctaoxodizincatedichromate-PPG (2 uses) (PH_PPG)

For discussion

9.3 Appointment of (co-)rapporteurs for authorisation applications

RAC/37/2016/09

Restricted room document

For agreement

Item 10 – AOB

Item 11 – Action points and main conclusions of RAC-37

Table with Conclusions and Action points from RAC-37

For adoption